Importantly, by facilitating tumor adaptation to environmental and therapeutic stressors, Pyk2 signaling may also contribute to resistance against conventional therapies, including temozolomide and radiation, further underscoring its relevance as a therapeutic target in GBM. The gene discussed is PTK2B; the disease is neoplasm.